For HER2‐positive advanced breast cancer, the preferred first‐line regimen should be dual HER2 blockade of trastuzumab and pertuzumab plus chemotherapy based on the CLEOPATRA trial.32 The gene discussed is ERBB2; the disease is breast carcinoma.